These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 3283407)

  • 1. Aluminum and iron overload in chronic dialysis.
    Ackrill P; Day JP; Ahmed R
    Kidney Int Suppl; 1988 Mar; 24():S163-7. PubMed ID: 3283407
    [No Abstract]   [Full Text] [Related]  

  • 2. Deferoxamine (DFO): the effectiveness for noninvasive diagnosis of aluminum-related bone disease, and for treatment of the disease.
    Marumo F; Umetani N; Sato N; Takahashi Y
    J UOEH; 1987 Mar; 9 Suppl():140-52. PubMed ID: 3602745
    [No Abstract]   [Full Text] [Related]  

  • 3. [The deferoxamine loading test as a non-invasive method for diagnosing Al-related bone disease in hemodialysis patients; efficacy of deferoxamine therapy for the disease].
    Umetani N; Sato N; Yoshida A; Marumo F
    Nihon Jinzo Gakkai Shi; 1988 Feb; 30(2):143-50. PubMed ID: 3386018
    [No Abstract]   [Full Text] [Related]  

  • 4. Aluminum-associated bone disease: considerations on the pathogenesis and the effects of deferoxamine treatment.
    Kurokawa K; Marumo F; Ogura Y; Ono T; Suzuki M
    J UOEH; 1987 Mar; 9 Suppl():133-9. PubMed ID: 3602744
    [No Abstract]   [Full Text] [Related]  

  • 5. Clearance of aluminum by hemodialysis: effect of desferrioxamine.
    Milliner DS; Hercz G; Miller JH; Shinaberger JH; Nissenson AR; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S100-3. PubMed ID: 3457984
    [No Abstract]   [Full Text] [Related]  

  • 6. Desferrioxamine treatment for aluminium and iron overload in uraemic patients by haemodialysis or haemofiltration.
    Baldamus CA; Schmidt H; Scheuermann EH; Werner E; Kaltwasser JP; Schoeppe W
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():382-6. PubMed ID: 3991527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of various treatment modalities on aluminium associated bone disease.
    Ihle BU; Buchanan MR; Stevens B; Becker GJ; Kincaid-Smith P
    Proc Eur Dial Transplant Assoc; 1983; 19():195-202. PubMed ID: 6348735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma aluminum and iron kinetics in hemodialyzed patients after i.v. infusion of desferrioxamine.
    Ciancioni C; Poignet JL; Mauras Y; Panthier G; Delons S; Allain P; Man NK
    Trans Am Soc Artif Intern Organs; 1984; 30():479-82. PubMed ID: 6533925
    [No Abstract]   [Full Text] [Related]  

  • 9. Aluminium overload influences cognitive function in patients on dialysis.
    Kambova L; Ionova D; Kirijakov Z
    Nephrol Dial Transplant; 1994; 9(9):1357. PubMed ID: 7816312
    [No Abstract]   [Full Text] [Related]  

  • 10. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.
    Sprague SM; Corwin HL; Wilson RS; Mayor GH; Tanner CM
    Arch Intern Med; 1986 Oct; 146(10):2063-4. PubMed ID: 3767553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The K/DOQI guidelines on diagnosis and treatment of aluminum bone disease in hemodialysis patients].
    Nakazawa R
    Clin Calcium; 2004 May; 14(5):738-43. PubMed ID: 15577035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of desferrioximine in dialysis-associated aluminium disease.
    Ackrill P; Day JP
    Contrib Nephrol; 1993; 102():125-34. PubMed ID: 8416177
    [No Abstract]   [Full Text] [Related]  

  • 13. Diagnosis and treatment of aluminium overload in end-stage renal failure patients.
    Nephrol Dial Transplant; 1993; 8 Suppl 1():1-4. PubMed ID: 8389013
    [No Abstract]   [Full Text] [Related]  

  • 14. Aluminum intoxication of bone in renal failure--fact or fiction?
    Malluche HH; Faugere MC; Smith AJ; Friedler RM
    Kidney Int Suppl; 1986 Feb; 18():S70-3. PubMed ID: 3458000
    [No Abstract]   [Full Text] [Related]  

  • 15. Indirect methods for the diagnosis of aluminum bone disease: plasma aluminum, the desferrioxamine infusion test, and serum iPTH.
    Nebeker HG; Andress DL; Milliner DS; Ott SM; Alfrey AC; Slatopolsky EA; Sherrard DJ; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S96-9. PubMed ID: 3458006
    [No Abstract]   [Full Text] [Related]  

  • 16. [Uremic encephalopathy, dialysis encephalopathy].
    Kinugasa E
    Nihon Rinsho; 2004 Jan; 62 Suppl():424-8. PubMed ID: 15011399
    [No Abstract]   [Full Text] [Related]  

  • 17. Desferrioxamine in the treatment of aluminum overload.
    Ackrill P; Day JP
    Clin Nephrol; 1985; 24 Suppl 1():S94-7. PubMed ID: 3842106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aluminum-associated bone disease: what's in a name?
    Quarles LD; Gitelman HJ; Drezner MK
    J Bone Miner Res; 1986 Oct; 1(5):389-90. PubMed ID: 3503553
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of desferrioxamine in the treatment of dialysis encephalopathy.
    Ackrill P; Ralston AJ; Day JP
    Kidney Int Suppl; 1986 Feb; 18():S104-7. PubMed ID: 3457985
    [No Abstract]   [Full Text] [Related]  

  • 20. New insights and strategies in the diagnosis and treatment of aluminium overload in dialysis patients.
    De Broe ME; D'Haese PC; Couttenye MM; Van Landeghem GF; Lamberts LV
    Nephrol Dial Transplant; 1993; 8 Suppl 1():47-50. PubMed ID: 8389021
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.